Journal
JOURNAL OF IMMUNOLOGICAL METHODS
Volume 476, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.jim.2019.112679
Keywords
Next-generation sequence; TCR beta; Neoantigen; Cancer immunotherapy
Categories
Funding
- Japan Society for the Promotion of Science (JSPS KAKENHI) [JP:15H04761, 16H06277]
- Shiga Prefecture (Japan)
- IMSUT (Institute of Medical Sciences, The University of Tokyo)
Ask authors/readers for more resources
Development of mechanism-driven biomarkers for immune checkpoint inhibitors (ICIs) in cancer immunotherapy requires sensitive and efficacious assays to identify tumor antigen (Ag)-specific T cells. We demonstrated the concept for a sensitive method to determine Ag-reactive T cell clones based on clonal expansion using model neoantigens (NeoAgs) rather than cytokine production. Sequential increase in T cell clonal frequencies following Ag stimulation was detected by next generation sequencing (NGS) of T cell receptor beta (TCR beta) complementarily-determining region 3 (CDR3), with a higher sensitivity than that of enzyme-linked immunospot (ELISPOT) by 100-fold. The TCR beta CDR3 sequences could represent useful markers to track dynamic changes during immunotherapy. The TCR beta NGS-based method could represent a novel platform both for the development of new biomarkers as well as several therapeutic options.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available